UCB: Clinical Trials & Research Profile
Biopharma Industry (Brussels, BE / Atlanta, GA) · Primary Focus: Immunology, Rheumatology, and Dermatology
| Clinical Trial Metric | Verified Public Record |
|---|---|
| Organization Type | Consolidated Trial Sponsor |
| Institutional Sector & Location | Biopharma Industry (Brussels, BE / Atlanta, GA) |
| Primary Therapeutic Area | Immunology, Rheumatology, and Dermatology |
| Active Phase II & III Studies | 22 active (14 recruiting now) |
| Total Tracked Studies (2018 to 2026) | 86 (54 with California sites) |
| Completed vs Early-Stopped Studies | 49 completed / 15 stopped (17.4% stop rate) |
| Median Closed Enrollment | 111 participants |
| FDA Drugs@FDA Original Approvals | 30 all-time (6 from 2018 to 2026) |
| Physical Hospital Site Disclosure | 100.0% named hospital slots |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.
Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI -> · AI for Healthcare · Healthcare Price & Patent Cliff Crosswalk